Search results
Antibiotic neomycin may protect against the flu, COVID-19
Medical News Today· 7 days agoViral respiratory infections are common and generally result in a few days of illness from which...
Pfizer lifts profit view on cost cuts, smaller drop in Paxlovid By Reuters
Investing.com· 2 days agoSales of Padcev, a treatment for advanced bladder cancer Pfizer (NYSE:PFE) gained through its $43...
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To...
Benzinga via Yahoo Finance· 2 days agoOn Wednesday, Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year...
INTREPID Alliance Landscape of Promising Antivirals in Clinical Development Reveals Gaps in Global...
Benzinga· 4 days agoBuilding on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies ...
Pfizer lifts 2024 profit view on cost cuts, higher COVID vaccine demand
WHTC 1450 Holland· 2 days ago(Reuters) -Pfizer lifted its annual profit forecast on Wednesday, banking on cost cuts and...
Charles Gore
Time Magazine· 1 day agoWhen new pharmaceutical drugs are invented in the future, Charles Gore hopes that every drug manufacturer will ask itself: How can we ensure this gets to...
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock...
Digital Journal· 3 days ago(NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully...
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 21 hours agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 1 day agoBMS strengthened its neuroscience portfolio with the acquisition of Karuna Therapeutics, and its lead asset, KarXT (trospium chloride + xanomeline), a...
Pfizer's first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Morningstar· 2 days agoPfizer Inc. on Wednesday reported first-quarter profit and sales that beat analyst expectations and raised its full-year earnings guidance as cancer and heart-disease drugs helped offset plummeting ...
